This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.
Mydayis
SKIP-FOR-NOW for users in this archetype with HIGH confidence.
Aliases (5)
Overview
What is Mydayis?
Mydayis is a triple-bead extended-release formulation of mixed amphetamine salts (same active ingredient as Adderall) approved by the FDA in 2017 for ADHD in adults and adolescents (≥13). Its three-stage release profile delivers up to 16 hours of coverage from a single morning dose.
Key Benefits
Provides longest-acting amphetamine ADHD treatment available, improving sustained attention, working memory, executive function, and impulse control across the full waking day. Single morning dosing eliminates the afternoon "crash" or need for booster doses common with shorter-acting stimulants.
Mechanism of Action
Mixed dextroamphetamine and levoamphetamine salts release in three sequential pulses, blocking dopamine and norepinephrine reuptake transporters (DAT/NET) and reversing them to drive monoamine efflux into the synapse, increasing prefrontal catecholamine signaling that underlies attentional control.
Pharmacokinetics
▸Brand options3 known
StatusSchedule II (US DEA) | Schedule II (Canada CDSA, equivalent products limited) | WADA-banned in-competition (S6 stimulant)
Peptide Interactions
(hypertensive crisis — absolute contraindication)
(loses MAO-B selectivity)
(methylphenidate, modafinil, high-dose caffeine — cumulative CV load)
(severe NT system overload, neurotoxicity, cardiac event risk)
(especially fluoxetine, paroxetine — strong CYP2D6 inhibitors raise amphetamine exposure)
(serotonin syndrome)
(sympathomimetic stacking)
(high-dose vit C, ammonium chloride — accelerate renal clearance, blunt effect unpredictably)
(bicarbonate, antacids — slow renal clearance, prolong/intensify unpredictably — *especially problematic with three-bead delivery* because PPI/antacid use ca…
Quality Indicators
Pharmacy-dispensed, intact packaging
Prescription tablets in original sealed packaging from a licensed pharmacy.
Generic vs branded
Generics are usually fine but bioavailability can vary slightly; track if you switch.
Unbranded blister or counterfeit risk
Counterfeit pharmaceuticals are a known issue; verify pharmacy and lot if buying internationally.
What to Expect
- Day 1PK-driven acute peak per administration. Verify dose tolerated.
- Week 1Steady-state reached for most daily-dosed pharma.
- Week 2-4Therapeutic effect established; titration window if needed.
- Long-termPeriodic monitoring per drug class (labs, BP, ECG as applicable).
Side Effects & Safety 9
Side Effects
- 1Insomnia ~25% (the differentiator from other MAS — directly attributable to 16-hr duration)
- 2Reduced appetite — extended into evening hours (worse than IR/XR for athletes)
- 3Dry mouth, increased thirst
- 4Headache — first 1-2 weeks
- 5Increased HR + BP — sustained throughout 14-16 hour window
- 6Anxiety / nervousness
- 7Bruxism / jaw clenching
- 8All Adderall-class less-common effects apply: palpitations, dizziness, weight loss, GI symptoms, reduced libido, ED, tremor, sweating, restlessness, dependence patterns
- 9Mood drop in late evening as third bead clears — some users report a "5 PM dip" before the bead 3 effect kicks in fully
When to Stop
- Cardiomyopathy / heart failure with chronic use — same case-report literature as Adderall; cumulative daily catecholamine load is *higher* per day on Mydayis than on Adderall IR (longer AUC), so the chronic CV risk is at least as high
- Sudden cardiac death — same FDA black-box class warning
- Stroke / MI, psychosis, mania switch, serotonin syndrome (with MAOIs/SSRIs/MDMA/tramadol), stimulant use disorder, withdrawal syndrome on discontinuation
- First 2 weeks: Sleep onset disruption (the differentiator), cardiovascular adjustment, anxiety, appetite
- Weeks 4-12: Tolerance development; insomnia rarely resolves with continued use unlike some other side effects
- Year 1+: Same cardiovascular structural concerns as Adderall, plus cumulative sleep debt from chronic 16-hr daily exposure
References
Mydayis FDA prescribing information (2017, updated 2023)
official PK, three-bead delivery system, indications, side effects, age restriction (13+).
View StudyWigal et al. 2017 — SHP-465 mixed amphetamine salts XR adult ADHD pivotal trial (J Clin Psychopharmacol)
adult RCT efficacy data.
View StudyWigal et al. 2018 — Adolescent SHP-465 study
13-17 age group efficacy + safety.
View StudyRoberts et al. 2020 — Pharmaceutical cognitive enhancement meta-analysis
d-amphetamine showed no overall significant cognitive enhancement effect in healthy adults; applies directly to Mydayis as same molecule.
View StudySmith & Farah 2011 — Are prescription stimulants smart pills?
landmark ceiling-effect critique applicable to MAS class.
View StudyReynolds et al. 2014 / 2015 — Adolescent amphetamine disrupts mPFC dopamine connectivity
brain-development concern at <25yo, applicable to all amphetamines including Mydayis.
View StudyLancet Psychiatry 2024 (Cortese et al.) — Adult ADHD pharmacotherapy network meta-analysis
00360-2/fulltext) — confirms amphetamines + methylphenidate as most efficacious for adult ADHD.
View Studyadderall.md
parent compound file with full mechanistic, evidence, side-effect, sourcing, pharmacogenomics, decision-matrix, and counter-argument detail. Mydayis inherits all of this; this file documents the de…
View StudyHow was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.